Aytu BioPharma, Inc.
AYTU Healthcare Drug Manufacturers Specialty & Generic
Aytu BioPharma, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $57.6 million, down 13.3% from fiscal 2025. In the quarter to June 2026, revenue grew 6.42%, EPS grew 100.0%, free cash flow grew 57.7% and total debt fell 21.9%, each against the same quarter a year earlier.
Follow AYTU
Aytu BioPharma, Inc. (AYTU) EV/Sales
As of 16 October 2026, Aytu BioPharma, Inc. (AYTU) trades at a EV/Sales of 0.3×. Over the past ten years it has ranged from −28.1× (September 2015) to 1,335,254,036× (April 2015); the current reading is higher than 53% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 0.3× | 335.86% |
| FY2025 | 0.1× | (59.00%) |
| FY2024 | 0.2× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.2× | (77.93%) |
| FY2021 | 0.9× | (18.44%) |
| FY2020 | 1.1× | (8.82%) |
| FY2019 | 1.2× | — |
| FY2018 | −1.0× | — |
| FY2017 | 33.4× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.3× | (28.89%) |
| Mar 2026 | 0.4× | 54.94% |
| Dec 2025 | 0.3× | 40.62% |
| Sep 2025 | 0.2× | 181.34% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IXHL Incannex Healthcare Inc. compare | −19.9× |
| UPC Universe Pharmaceuticals INC compare | −0.2× |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. compare | n/m |
| BGXXQ Bright Green Corporation compare | n/m |
| RMTI Rockwell Medical, Inc. compare | 0.2× |
| BFRI Biofrontera Inc. compare | 0.2× |
| AYTU Aytu BioPharma, Inc. | 0.3× |
| CPHI China Pharma Holdings, Inc. compare | 8.1× |
| TXMD TherapeuticsMD, Inc. compare | 85.1× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)